Abstract

    Open Access Mini Review Article ID: SJGGT-4-114

    Lenalidomide as potential treatment in small cell neuroendocrine lung cancer with del 5q

    Paul Hartel*

    Lung cancer is a leading cause of cancer deaths world-wide, with the carcinogens in tobacco smoke playing a major etiologic role. Genetic changes responsible for carcinogenesis include activation of proto-oncogenes and inactivation of tumor suppressor genes. Tumor suppressor gene inactivation is contributed to, in part, by loss of chromosomal DNA. While cytogenetic findings in small cell neuroendocrine lung carcinoma are complex, 5q deletion is among the most frequently identified [1,2].

    Keywords:

    Published on: Jul 11, 2018 Pages: 2-3

    Full Text PDF Full Text HTML DOI: 10.17352/sjggt.000014
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on SJGGT